Literature DB >> 27466299

Clinical and Laboratory Profile of Urinary Tract Infections Associated with Extended Spectrum β-Lactamase Producing Escherichia coli and Klebsiella pneumoniae.

Sulaiman Ali Al Yousef1, Sabry Younis1, Eman Farrag1, Husseiny Sh Moussa2, Faten Sayed Bayoumi3, Ahmed Mohamed Ali4.   

Abstract

BACKGROUND: Urinary tract infection (UTI) is mainly due to invasion of the urethra, bladder or kidneys by pathogens. The emergence of extended spectrum β-lactamases (ESBL) is responsible for frequently observed empirical therapy failures.
OBJECTIVES: To study the clinical and laboratory characteristics of UTIs caused by ESBL producing Escherichia coli (E. coli) and Klebsiella pneumonia (K. pneumonia).
METHODS: A cross-sectional clinical and laboratory study was performed at King Khalid Hospital, Hafr Al Batin, Saudi Arabia between March 2014 to October 2015. A total of 908 urine samples from suspected UTI patients was collected. Samples were isolated on Cysteine Electrolyte-Deficient (CLED) agar. Positive cultures were identified and tested for antimicrobial susceptibility by MicroScan(®) WalkAway-96 SI System, and then ESBL was confirmed by double disc synergy test (DDST) and phenotypic confirmatory disc diffusion test (PCDDT).
RESULTS: A total of 680 samples (288 males and 392 females) were culture positive. 520 samples (76.5%) of E. Coli were found and 160 samples of K. pneumonia were identified (23.5%). ESBL testing showed 296 (218 E. coli and 78 K. pneumonia) samples of positive isolates. Non-ESBL isolates showed highest resistance to ampicillin followed by Mezocillin and Trimethoprim-Sulphamethoxazole-which are usually recommended as the initial treatment of UTI-while ESBL isolates showed resistance to third generation cephalosporin along with Ampicillin and Trimethoprim-Sulphamethoxazole. In this study, four significant risk factors for ESBL infection such as diabetes, recurrent UTI, previous use of antibiotics and previous hospitalization were found.
CONCLUSION: Identifying the risk factors and antibiotic susceptibility patterns associated with ESBL producing E. coli and K. pneumonia is a useful guide for treatment strategy and control of ESBL UTI.
© 2016 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  E. coli; ESBL; K. pneumonia; UTI

Mesh:

Substances:

Year:  2016        PMID: 27466299

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  13 in total

1.  Bacterial Profiles and Their Associated Factors of Urinary Tract Infection and Detection of Extended Spectrum Beta-Lactamase Producing Gram-Negative Uropathogens Among Patients with Diabetes Mellitus at Dessie Referral Hospital, Northeastern Ethiopia.

Authors:  Mekuanent Alemu; Melaku Ashagrie Belete; Solomon Gebreselassie; Assefa Belay; Daniel Gebretsadik
Journal:  Diabetes Metab Syndr Obes       Date:  2020-08-19       Impact factor: 3.168

2.  A Three-Year Look at the Phylogenetic Profile, Antimicrobial Resistance, and Associated Virulence Genes of Uropathogenic Escherichia coli.

Authors:  Lorina I Badger-Emeka; Naheed Kausar; Edric Estrella; Glenda Belgira Angeles
Journal:  Pathogens       Date:  2022-05-30

3.  Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014.

Authors:  Qiwen Yang; Hui Zhang; Yao Wang; Zhipeng Xu; Ge Zhang; Xinxin Chen; Yingchun Xu; Bin Cao; Haishen Kong; Yuxing Ni; Yunsong Yu; Ziyong Sun; Bijie Hu; Wenxiang Huang; Yong Wang; Anhua Wu; Xianju Feng; Kang Liao; Yanping Luo; Zhidong Hu; Yunzhuo Chu; Juan Lu; Jianrong Su; Bingdong Gui; Qiong Duan; Shufang Zhang; Haifeng Shao; Robert E Badal
Journal:  BMC Infect Dis       Date:  2017-03-06       Impact factor: 3.090

4.  An evaluation of E. coli in urinary tract infection in emergency department at KAMC in Riyadh, Saudi Arabia: retrospective study.

Authors:  Menyfah Q Alanazi; Fulwah Y Alqahtani; Fadilah S Aleanizy
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-02-09       Impact factor: 3.944

5.  Prevalence and risk factors for CTX-M gram-negative bacteria in hospitalized patients at a tertiary care hospital in Kilimanjaro, Tanzania.

Authors:  Tolbert Sonda; Happiness Kumburu; Marco van Zwetselaar; Michael Alifrangis; Blandina T Mmbaga; Ole Lund; Frank M Aarestrup; Gibson Kibiki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-20       Impact factor: 3.267

6.  Risk factors and molecular features of extended-spectrum beta-lactamase producing bacteria at southwest of Saudi Arabia.

Authors:  Saleh M Al-Garni; Mabrouk M Ghonaim; Mohamed Morsi M Ahmed; Ali S Al-Ghamdi; Farooq A Ganai
Journal:  Saudi Med J       Date:  2018-12       Impact factor: 1.484

7.  Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples.

Authors:  Mohammad Javad Gharavi; Javad Zarei; Parisa Roshani-Asl; Zahra Yazdanyar; Masoud Sharif; Niloufar Rashidi
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

8.  Antimicrobial Surveillance for Bacterial Uropathogens in Ha'il, Saudi Arabia: A Five-Year Multicenter Retrospective Study.

Authors:  Abdulrahman S Bazaid; Amir Saeed; Abdulaziz Alrashidi; Abdulkarim Alrashidi; Khalid Alshaghdali; Sahar A Hammam; Talal Alreshidi; Munif Alshammary; Abdullah Alarfaj; Rawan Thallab; Abdu Aldarhami
Journal:  Infect Drug Resist       Date:  2021-04-16       Impact factor: 4.003

9.  Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: Prevalence, risk factors, and resistances.

Authors:  Iñigo Pérez Heras; Juan Carlos Sanchez-Gomez; Pedro Beneyto-Martin; Laura Ruano-de-Pablo; Begoña Losada-Pinedo
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review.

Authors:  Claudia Truppa; Mahmoud N Abo-Shehada
Journal:  BMC Infect Dis       Date:  2020-12-09       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.